Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer
G. Thomas Budd, MD
Published Online: Tuesday, June 25, 2013
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses the background and results of the S0221 trial in breast cancer.
Previously, Budd says, researchers analyzed two dose-dense regimens and found that treatment with doxorubicin-cyclophosphamide followed by paclitaxel given every two weeks was more effective than the same regimen with all drugs given every three weeks.
Another trial looked at the same regimen given weekly and compared it to treatment every three weeks. In this analysis, weekly treatment was better than treatment every three weeks.
In the S0221 trial, researchers compared these two schools of thought, Budd says. The trial showed that in terms of efficacy, these two regimens produced similar outcomes, but the side effects differed.
As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.